Latest Articles

Publication Date
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerEndo Test for Endometriosis Receives $0.5m Grant - ABN Newswire

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerEndo Test for Endometriosis Receives $0.5m Grant ABN Newswire

Published: Nov. 6, 2025, 3:51 a.m.
Evolution of an ovarian endometriotic cyst into clear cell carcinoma with squamous differentiation across two pregnancies: A case report.

Ovarian clear cell carcinoma (OCCC) during pregnancy is exceedingly rare, particularly when accompanied by squamous differentiation, with only a limited number of cases reported in the English literature to date.

Published: Nov. 6, 2025, midnight
Real Time Nerve Mapping for Endometriosis Involving the Sciatic & Pudendal Nerves.

To demonstrate a standardized and reproducible technique utilizing intraoperative neurophysiological monitoring (IONM) with real-time nerve mapping to improve the safety of deep infiltrating endometriosis surgery and facilitate the preservation of …

Published: Nov. 6, 2025, midnight
Associations of PFAS exposure with obstetric and birth outcomes in the Japan Environment and Children's Study (JECS): Is maternal endometriosis an effect modifier?

Per- and polyfluoroalkyl substances (PFAS) are reportedly associated with adverse obstetric outcomes, including premature labor and gestational diabetes. We aimed to evaluate associations of maternal PFAS exposure with obstetric and …

Published: Nov. 6, 2025, midnight
Sonographic and Clinical Progression of Adenomyosis and Coexisting Endometriosis: Long-Term Insights and Management Perspectives.

Objectives: To evaluate the impact of hormonal therapy on the evolution of painful symptoms in premenopausal women with adenomyosis, with or without concomitant endometriosis, over an 18-month follow-up period. This …

Published: Nov. 6, 2025, midnight
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - The Manila Times

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results The Manila Times

Published: Nov. 5, 2025, 9:37 p.m.
Metabolome analysis as a potential source of endometriosis biomarkers with the use of multiomics approach in its diagnosis.

Endometriosis poses diagnostic challenges. This study aimed to analyze the metabolomic profiles of plasma and peritoneal fluid samples obtained from women with endometriosis compared to controls. Our multicenter study involved …

Published: Nov. 5, 2025, midnight
Ferroptosis in reproductive system disorders: Pathological roles and therapeutic potential.

Ferroptosis, as an iron-dependent programmed cell death, plays a significant role in reproductive system diseases. It's involved in the pathological processes of various reproductive system diseases by affecting the survival …

Published: Nov. 5, 2025, midnight
Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern.

Biomaterials for drug delivery offer significant advantages over conventional medications, including enhanced cellular uptake, improved drug stability, targeted delivery, and controlled drug release. Cutting-edge nanodrugs delivery approaches such as drugs …

Published: Nov. 5, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!